Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

Symptomatic cytomegalovirus gastrointestinal infection with positive quantitative real- time PCR findings in apparently immunocompetent patients: a case.

Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection D.K.-H. Wong, J. Fung, C.-K. Lee, W.-K.

I.J. Schalk Clinical Microbiology and Infection

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Migrant health—a cause for concern?

Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics Y.H. van Beurden, S. Nezami,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Candida glabrata fungaemia in intensive care units

Hepatitis B and C virus-related carcinogenesis

Virological tools to diagnose and monitor hepatitis C virus infection

Refugee crisis and re-emergence of forgotten infections in Europe

Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance—a retrospective population based study.

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

R. Cantón Clinical Microbiology and Infection

Multicentre surveillance of prevalence of the 23S rRNA A2058G and A2059G point mutations and molecular subtypes of Treponema pallidum in Taiwan, 2009–2013

Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection Y.W.

Longitudinal investigation of nasopharyngeal methicillin-resistant Staphylococcus aureus colonization in early infancy: The PATCH birth cohort study

Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure Y.-C. Wang, Y.-T.

Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013 L.E.B. Nabarro, R.A. Lever, M. Armstrong,

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study M.-C. Tsai,

Vector control: a cornerstone in the malaria elimination campaign

Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis J. Jung, M.Y. Kim, H.J. Lee, Y.S. Park, S.-O.

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

Isospora belli Clinical Microbiology and Infection

Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination M.-R. Lee,

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

G. Ippolito, A. Zumla, S. Lanini Clinical Microbiology and Infection

Clinical and microbiological characteristics of Nocardiosis including those caused by emerging Nocardia species in Taiwan, 1998–2008 C.-K. Tan, C.-C.

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit E. Theocharidou, B. Agarwal, G. Jeffrey,

A. Pierangeli, F. Cannella, C. Scagnolari, M. Gentile, I. Sciandra, G

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Metagenomics and probiotics

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Hepatitis B and C virus-related carcinogenesis

Detection of Wolbachia genes in a patient with non-Hodgkin's lymphoma

J. Garau Clinical Microbiology and Infection

Systematic review of antibiotic consumption in acute care hospitals

Treatment of hepatitis B in patients with chronic kidney disease

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Abstracts cont. Clinical Microbiology and Infection

Current experience in treating invasive zygomycosis with posaconazole

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy L. Boglione,

Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic.

S. M. Bartsch, J. A. McKinnell, L. E. Mueller, L. G. Miller, S. K

Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS M. Rybicka,

Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013 U. Fedeli, E. Schievano,

Statin use and clinical outcomes among pneumonia patients

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Methods for guideline development

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Volume 62, Issue 4, Pages (April 2015)

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Volume 85, Issue 5, Pages (May 2014)

J.L. Balcázar Clinical Microbiology and Infection

Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China Y. Hu,

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Presentation transcript:

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C. Tsai, C.-H. Chen, P.-L. Tseng, C.-H. Hung, K.-W. Chiu, J.-H. Wang, S.-N. Lu, C.-M. Lee, K.-C. Chang, Y.-H. Yen, M.-T. Lin, Y.-P. Chou, T.-H. Hu Clinical Microbiology and Infection Volume 22, Issue 1, Pages 95.e1-95.e7 (January 2016) DOI: 10.1016/j.cmi.2015.05.035 Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Comparison the estimated glomerular filtration rate (eGFR) between entecavir (ETV), telbivudine (LdT) or tenofovir (TDF) -naive chronic hepatitis B (CHB). (a) Overall; (b) in eGFR >90 mL/min/1.73 m2 (c) in chronic kidney disease stage II. Clinical Microbiology and Infection 2016 22, 95.e1-95.e7DOI: (10.1016/j.cmi.2015.05.035) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Comparison the change of estimated glomerular filtration rate (eGFR) between entecavir (ETV), telbivudine (LdT), or tenofovir (TDF)-naive chronic hepatitis B (CHB) from baseline to last visit. (a) Overall, (b) in eGFR >90 mL/min/1.73 m2, (c) in chronic kidney disease stage II, (d) without chemotherapy. Clinical Microbiology and Infection 2016 22, 95.e1-95.e7DOI: (10.1016/j.cmi.2015.05.035) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 3 Comparison cumulative hepatocellular carcinoma (HCC) incidence in naive chronic hepatitis B (CHB). (a) Overall, (b) between entecavir, telbivudine, and entecavir, (c) between virological breakthrough and non-virological breakthrough, and (d) between cirrhosis and non-cirrhosis. Clinical Microbiology and Infection 2016 22, 95.e1-95.e7DOI: (10.1016/j.cmi.2015.05.035) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions